FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FGEN
- Previous Close: $23.80
- 50 Day Moving Average: $23.83
- 200 Day Moving Average: $20.77
- 52-Week Range: $14.50 - $25.70
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.69
- P/E Growth: 0.00
- Market Cap: $1.50B
- Outstanding Shares: 63,160,000
- Beta: 1.75
- Net Margins: -45.93%
- Return on Equity: -40.38%
- Return on Assets: -16.66%
Companies Related to FibroGen:
- Debt-to-Equity Ratio: 0.49%
- Current Ratio: 4.11%
- Quick Ratio: 4.11%
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?
4 equities research analysts have issued 12-month target prices for FibroGen's stock. Their forecasts range from $31.00 to $52.00. On average, they anticipate FibroGen's stock price to reach $38.25 in the next twelve months.
When will FibroGen announce their earnings?
FibroGen is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns FibroGen stock?
FibroGen's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.43%), State Street Corp (2.16%), Janus Capital Management LLC (2.14%), EcoR1 Capital LLC (1.09%), Pinnacle Associates Ltd. (1.08%) and Renaissance Technologies LLC (0.53%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Thomas F Kearns, Jr.
Who sold FibroGen stock? Who is selling FibroGen stock?
FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC and Pinnacle Associates Ltd.. Company insiders that have sold FibroGen stock in the last year include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr.
Who bought FibroGen stock? Who is buying FibroGen stock?
FibroGen's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Bogle Investment Management L P DE, State Street Corp, A.R.T. Advisors LLC, Oxford Asset Management, Trexquant Investment LP and Russell Investments Group Ltd..
How do I buy FibroGen stock?
Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of FibroGen stock cost?
One share of FibroGen stock can currently be purchased for approximately $23.80.